We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

58 hedge funds and large institutions have $33.1M invested in Regulus Therapeutics in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 20 increasing their positions, 19 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 19

0.05% less ownership

Funds ownership: 0.37% → 0.32% (-0.05%)

15% less funds holding

Funds holding: 68 → 58 (-10)

37% less capital invested

Capital invested by funds: $52.9M → $33.1M (-$19.8M)

40% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 15

87% less call options, than puts

Call options by funds: $14K | Put options by funds: $107K

Holders
58
Holders Change
-10
Holders Change %
-14.71%
% of All Funds
1.44%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
20
Reduced
19
Closed
15
Calls
$14K
Puts
$107K
Net Calls
-$93K
Net Calls Change
+$156K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.37M
2
EC
EcoR1 Capital
California
+$2.39M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.34M
4
BI
BVF Inc
California
+$988K
5
ARTA
A.R.T. Advisors
New York
+$295K

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$10.5M
2
Axa
Axa
France
-$2.4M
3
Millennium Management
Millennium Management
New York
-$847K
4
BCM
Bridgeway Capital Management
Texas
-$342K
5
Renaissance Technologies
Renaissance Technologies
New York
-$322K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$13.1M +$2.28K +12 +0%
BlackRock
2
BlackRock
New York
$3.51M +$3.37M +17,684 +80,382%
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.52M +$1.34M +7,028 +124%
EC
4
EcoR1 Capital
California
$2.49M +$2.39M +12,583 New
SDIC
5
South Dakota Investment Council
South Dakota
$2.19M +$295K +1,551 +16%
Wells Fargo
6
Wells Fargo
California
$1.29M +$148K +778 +14%
BI
7
BVF Inc
California
$1.03M +$988K +5,192 New
RPAM
8
Rhenman & Partners Asset Management
Sweden
$979K +$199K +1,046 +27%
State Street
9
State Street
Massachusetts
$959K +$45.3K +238 +5%
Northern Trust
10
Northern Trust
Illinois
$691K +$24.4K +128 +4%
ARTA
11
A.R.T. Advisors
New York
$456K +$295K +1,552 +206%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$438K +$13.9K +73 +3%
WS
13
Wedbush Securities
California
$299K +$148K +779 +107%
California Public Employees Retirement System
14
California Public Employees Retirement System
California
$293K -$12.2K -64 -4%
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$270K -$3.04K -16 -1%
Goldman Sachs
16
Goldman Sachs
New York
$210K -$160K -842 -44%
TCIM
17
TIAA CREF Investment Management
New York
$203K – – –
Renaissance Technologies
18
Renaissance Technologies
New York
$195K -$322K -1,691 -63%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$192K -$26.6K -140 -13%
Tudor Investment Corp
20
Tudor Investment Corp
Connecticut
$178K +$97.5K +512 +132%
TA
21
Teachers Advisors
New York
$152K +$31.8K +167 +28%
California State Teachers Retirement System (CalSTRS)
22
California State Teachers Retirement System (CalSTRS)
California
$131K -$190 -1 -0.2%
Morgan Stanley
23
Morgan Stanley
New York
$102K -$103K -541 -51%
Charles Schwab
24
Charles Schwab
California
$102K – – –
RhumbLine Advisers
25
RhumbLine Advisers
Massachusetts
$92K +$25.3K +133 +40%
1
2 3

RGLS Hedge Fund Activity: Q1 2017 in Review

58 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q1 2017, worth a combined $33.1M — down 37% from $52.9M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of RGLS and 9 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 20 added.

The largest buyer was BlackRock, adding an estimated $3.37M. The largest seller was Wellington Management Group, exiting entirely with an estimated $10.5M sold.

  • 58 institutional investors held Regulus Therapeutics (RGLS) as of Q1 2017, down from 68 in Q4 2016.
  • Funds reported $33.1M of Regulus Therapeutics stock for Q1 2017, down 37% quarter-over-quarter.
  • 9 funds opened new Regulus Therapeutics positions in Q1 2017 and 15 closed out, a net change of -6 holders.
  • The largest Regulus Therapeutics buyer in Q1 2017 was BlackRock, an estimated $3.37M added.
  • The largest Regulus Therapeutics seller in Q1 2017 was Wellington Management Group, an estimated $10.5M sold.

Based on aggregated 13F filings for Q1 2017.